Initial Palivizumab Dose Administration in Outpatient Clinic After Hospital Discharge.

ABSTRACT:

Background

Palivizumab provides passive immunity for respiratory syncytial virus (RSV), but poor adherence compromises protection. A hospital initiative promoted administration of first palivizumab doses at an outpatient clinic immediately after discharge. The objectives of this study were to evaluate the impact of the initiative on location and timing of first palivizumab dose, patient adherence, reimbursement, acquisition cost and RSV-positive hospital readmissions.

Methods

This retrospective cohort study included pediatric patients who received palivizumab from 2012 to 2016. Three groups were compared: "before initiative," "transition" and "after initiative." Patients who did not qualify for palivizumab or who were eligible for palivizumab in previous RSV seasons were exc

SUBMITTER: Stockton W 

PROVIDER: S-EPMC6150837 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature